FDA Approves Finerenone for Type 1 Diabetes-Related Kidney Disease

The US Food and Drug Administration has approved finerenone (Kerendia) for adults with chronic kidney disease (CKD) associated with type 1 diabetes. This approval represents a significant milestone: it is the first new treatment option specifically developed for type 1 diabetes-related kidney disease to reach patients in more than 30 years.

Chronic kidney disease is a serious complication for some people with type 1 diabetes. The condition involves progressive loss of kidney function, and until now, treatment options have been extremely limited. The approval of finerenone expands the therapeutic toolkit available to patients and their doctors.

Finerenone works by reducing albumin in the urine—a measurement called UACR (urine albumin-to-creatinine ratio). Albumin in the urine is an early sign of kidney damage and is associated with progression of kidney disease. By reducing UACR levels, finerenone is expected to slow the advancement of kidney disease in people with type 1 diabetes.

This mechanism of action builds on evidence gathered from clinical trials of finerenone in type 2 diabetes, where reductions in UACR have been linked to improved kidney outcomes. The new approval extends these findings to the type 1 diabetes population.

The FDA approval is based on results from the FINE-ONE trial, a large-scale international study. FINE-ONE was a randomized, double-blind, placebo-controlled Phase III trial that enrolled adult patients with chronic kidney disease associated with type 1 diabetes across multiple medical centers worldwide.

Dr. Janet McGill, Co-Chair of the study's Executive Committee and a professor of endocrinology at Washington University School of Medicine, emphasized the importance of this approval: "For more than three decades, people with chronic kidney disease and type 1 diabetes have had limited options to address the risk of kidney disease progression. The approval of finerenone provides an important new treatment option for a population that has continued to face substantial unmet need."

This approval represents meaningful progress for people living with both type 1 diabetes and chronic kidney disease. A population that has historically had few treatment options now has access to a therapy specifically studied and approved for their condition.

If you have type 1 diabetes and kidney disease, this approval may be worth discussing with your healthcare provider. They can help determine whether finerenone is appropriate for your individual situation and how it fits into your overall treatment plan.

Origin: medicaldialogues.in (News report). Evidence: News report — unverified, pending corroboration. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.